In glioma cells, the C-terminal of Cx43 recruits c-Src together with its physiological inhibitors CSK and PTEN, causing the inhibition of c-Src and its pleiotropic oncogenic pathways by decreasing the phosphorylation levels of Y416 (activating) and increasing those of Y527 (inhibitory) residues [9,10,11]. This evidence concerns the gene SRC and central nervous system cancer.